CytomX FY2022 revenue $53.2M; cash $194M; AbbVie terminates CX-2029; new Moderna/Regeneron deals

CytomX Therapeutics, Inc.

FY2022 revenue $53.2M (+43% YoY); cash $194M vs $305M at Dec 2021.
Restructuring substantially complete; $7.7M in charges incurred in 2022.
AbbVie terminates CX-2029 collaboration; CytomX regains full rights to CD71 program.
CX-904 Phase 1 dose escalation progressing; IND filings for CX-801 & CX-2051 expected 2H 2023.
New collaborations: Moderna ($35M upfront) and Regeneron ($30M upfront) with up to $1.2B and $2B milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 27, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.